ArticleResearch and practice in thrombosis and haemostasis2020
Anticoagulation practice patterns in COVID-19: A global survey.
Article in Research and practice in thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Anticoagulants for people hospitalised with COVID-19: a rapid reviewThe Cochrane database of systematic reviews · 2022Pooled it
- Neurological Complications in COVID-19 Patients With ECMO Support: A Systematic Review and Meta-Analysis.Heart, lung & circulation · 2022Pooled it
- Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis.Thrombosis and haemostasis · 2021Pooled it
- Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.The New England journal of medicine · 2021Trial
- Measurement of plasma direct oral anticoagulants concentrations in real-world clinical and laboratory settings on a 24/7 basis: a 10-year experience.Journal of thrombosis and thrombolysis · 2026Article
- Outcomes of Left Ventricular Assist Devices as Destination Therapy: A Systematic Review with Meta-Analysis.Life (Basel, Switzerland) · 2025Review
- Antithrombotic Use Patterns in COVID-19 Patients from Spain: A Real-World Data Study.Journal of clinical medicine · 2024Article
- The Collateral Benefit of COVID Pandemic: Improved Pharmacological Venous Thromboembolism Prophylaxis Practices in Non-COVID Patients.International journal of general medicine · 2023Article
- The intensity of anticoagulant dosing in hospitalized patients with COVID-19: An observational, comparative effectiveness study.Journal of hospital medicine · 2023Observational
- Approach to Thromboprophylaxis for Prevention of Venous Thromboembolism in COVID-19: Global Updates and Clinical Insights from India.Clinics and practice · 2022Review
- Comparison of Higher-Than-Standard to D-Dimer Driven Thromboprophylaxis in Hospitalized Patients With COVID-19.Hospital pharmacy · 2022Article
- The COVID-19 Patient in the Surgical Intensive Care Unit.The Surgical clinics of North America · 2022Review
- Screening the Potential Biomarkers of COVID-19-Related Thrombosis Through Bioinformatics Analysis.Frontiers in genetics · 2022Article
- Biomarkers of Cardiac Injury, Renal Injury, and Inflammation Are Strong Mediators of Sex-Associated Death in COVID-19.Frontiers in cardiovascular medicine · 2022Article
- Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis.Thrombosis journal · 2021Article
- The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.Journal of thrombosis and haemostasis : JTH · 2021Article
- Anticoagulation in COVID-19: reaction to the ACTION trial.Lancet (London, England) · 2021Article
- Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study.Journal of thrombosis and haemostasis : JTH · 2021Article
- Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia.Chest · 2021Observational
- SARS-COV-2-associated coagulopathy and thromboembolism prophylaxis in children: A single-center observational study.Journal of thrombosis and haemostasis : JTH · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 13 institutions in 6 countries.
Funding
Abstract
Background: Best practice for prevention, diagnosis, and management of venous thromboembolism (VTE) in patients with coronavirus disease 2019 (COVID-19) is unknown due to limited published data in this population. Objectives: We aimed to assess current global practice and experience in management of COVID-19-associated coagulopathy to identify information to guide prospective and randomized studies. Methods: Physicians were queried about their current approach to prophylaxis, diagnosis, and treatment of VTE in patients with COVID-19 using an online survey tool distributed through multiple international organizations between April 10 and 14, 2020. Results: Five hundred fifteen physicians from 41 countries responded. The majority of respondents (78%) recommended prophylactic anticoagulation for all hospitalized patients with COVID-19, with most recommending use of low-molecular-weight heparin or unfractionated heparin. Significant practice variation was found regarding the need for dose escalation of anticoagulation outside the setting of confirmed or suspected VTE. Respondents reported the use of bedside testing when unable to perform standard diagnostic imaging for diagnosis of VTE. Two hundred ninety-one respondents reported observing thrombotic complications in their patients, with 64% noting that the complication was pulmonary embolism. Of the 44% of respondents who estimated incidence of thrombosis in patients with COVID-19 in their hospital, estimates ranged widely from 1% to 50%. One hundred seventy-four respondents noted bleeding complications (34% minor bleeding, 14% clinically relevant nonmajor bleeding, and 12% major bleeding). Conclusion: Well-designed epidemiologic studies are urgently needed to understand the incidence and risk factors of VTE and bleeding complications in patients with COVID-19. Randomized clinical trials addressing use of anticoagulation are also needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.